Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532873 | 0.81 | NPC1 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2MEN1 | |
| SCHEMBL3656969 | 0.80 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2854834 | 0.80 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MAPKAPK2MEN1 | |
| SCHEMBL4396319 | 0.80 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 | |
| SCHEMBL85663 | 0.80 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 | |
| SCHEMBL20639714 | 0.79 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3MAPKAPK2 | |
| SCHEMBL16570287 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 | |
| SCHEMBL5767402 | 0.79 | ADRB2 (0.52) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 | |
| Hydrochloric Acid SCHEMBL1583516 | 0.79 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MAPKAPK2ALDH1A1 | |
| SCHEMBL8286227 | 0.79 | ADRB1 (0.52) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1534292-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-04-02 | — | — | EP | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| EP-1578429-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1511745-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7109233-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| EP-1511492-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| WO-2003103574-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104257-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003099844-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003097593-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| CN-1416346-A | Peotease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | CN | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | SLC6A2 4681/4885SLC6A4 3780/4885SLC6A3 3919/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | SLC6A2 4577/4885SLC6A4 3642/4885SLC6A3 3594/4885 |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | SLC6A2 4779/4885SLC6A4 4512/4885SLC6A3 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.